ELTXElicio Therapeutics, Inc.

Nasdaq elicio.com


$ 7.88 $ 0.39 (5.19 %)    

Friday, 31-May-2024 15:57:22 EDT
QQQ $ 454.82 $ -0.84 (-0.19 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.76 (0.91 %)
TLT $ 91.26 $ 0.61 (0.68 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 7.9
$ 7.52
$ 0.00 x 0
$ 0.00 x 0
$ 7.52 - $ 7.90
$ 2.96 - $ 22.65
12,044
na
81.16M
$ 1.80
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-29-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-12-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-17-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-30-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 elicio-therapeutics-on-may-23--announced-preliminary-data-from-ongoing-amplify-7p-phase-1a-study-of-eli-002-7p-in-patients-with-mkras-driven-solid-tumors-at-2024-asco-annual-meeting

ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell respons...

 hc-wainwright--co-reiterates-buy-on-elicio-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $10 price...

 elicio-therapeutics-q1-2024-adj-eps-115-misses-109-estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(1.15) per share which missed the analyst consensus estimate of...

 hc-wainwright--co-maintains-buy-on-elicio-therapeutics-lowers-price-target-to-10

HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price tar...

 elicio-therapeutics-to-present-new-preliminary-data-from-the-ongoing-amplify-7p-phase-12-study-of-eli-002-7p-in-patients-with-mkras-driven-solid-tumors-at-the-2024-asco-annual-meeting

Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")))), a clinical-stage biotechnology c...

 elicio-therapeutics-to-present-updated-clinical-t-cell-and-antigen-spreading-response-data-from-the-ongoing-amplify-201-phase-1-study-of-eli-002-and-preclinical-data-on-eli-007-and-eli-008-at-the-aacr-annual-meeting

68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells 84% of patients treated with ELI-002 devel...

 oppenheimer-reiterates-perform-on-elicio-therapeuticsto-perform

Oppenheimer analyst Matthew Biegler reiterates Elicio Therapeutics (NASDAQ:ELTX) from Perform to Perform.

 elicio-therapeutics-publishes-preclinical-data-demonstrating-tcr-t-cell-therapy-in-combination-with-lymph-node-targeted-amphiphile-immunotherapy-enhanced-anti-tumor-function-and-eradicated-solid-tumors

Published data shows lymph node-targeted Amphiphile ("AMP")-peptide and CpG combination with TCR-T cell therapy led to ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION